Measuring the Pharmacodynamic Effects of a Novel Hsp90 Inhibitor on HER2/neu Expression in Mice Using (89)Zr-DFO-Trastuzumab

BACKGROUND: The positron-emitting radionuclide (89)Zr (t (1/2) = 3.17 days) was used to prepare (89)Zr-radiolabeled trastuzumab for use as a radiotracer for characterizing HER2/neu-positive breast tumors. In addition, pharmacodynamic studies on HER2/neu expression levels in response to therapeutic d...

Descripción completa

Detalles Bibliográficos
Autores principales: Holland, Jason P., Caldas-Lopes, Eloisi, Divilov, Vadim, Longo, Valerie A., Taldone, Tony, Zatorska, Danuta, Chiosis, Gabriela, Lewis, Jason S.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810330/
https://www.ncbi.nlm.nih.gov/pubmed/20111600
http://dx.doi.org/10.1371/journal.pone.0008859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810330/
https://www.ncbi.nlm.nih.gov/pubmed/20111600
http://dx.doi.org/10.1371/journal.pone.0008859

Ejemplares similares